A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization

TL;DR: The initial single center experience with Yttrium-90 microspheres radioembolization is reported as downstaging and bridging method for hepatocellular carcinoma prior liver surgery, resection or liver transplantation.

TL;DR: In this paper , the authors performed a retrospective review of patients receiving programmed cell death 1 inhibitor (PD1) before liver transplantation for HCC in their center and analyzed the data of these patients with the purpose of investigating the safety and feasibility of preoperative PD1 inhibitor among liver transplant recipients and exploring the preoperative correlation ICIs and the postoperative risk of rejection and immune-related graft loss.

TL;DR: The overall feasibility of combining preoperative SIRT and surgery was limited and did not increase expected operative morbidity, but post-SIRT, a third of patients were refuted for surgery.

TL;DR: The following is a review of LRT in CRLM, including salient features, advantages, limitations, current roles, and future considerations.

TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.

TL;DR: Liver transplantation is an effective treatment for small, unresectable hepatocellular carcinomas in patients with cirrhosis and after four years, the actuarial survival rate was 75 percent and the rate of recurrence-free survival was 83 percent.

TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.